Right versus left atrial pacing in patients with sick sinus syndrome and paroxysmal atrial fibrillation (Riverleft study): study protocol for randomized controlled trial

• Published in: Trials Vol. 15; no. 1; p. 445
• Main Authors: Ramdjan, Tanwier T T K, van der Does, Lisette J M E, Knops, Paul, Res, Jan C J, de Groot, Natasja M S
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 17.11.2014; BioMed Central
• Subjects: Anti-arrhythmia drugs; Atrial Appendage - physiopathology; Atrial Fibrillation - diagnosis; Atrial Fibrillation - physiopathology; Atrial Fibrillation - prevention & control; Atrial Function, Left; Atrial Function, Right; Cardiac Pacing, Artificial - methods; Clinical Protocols; Coronary Sinus - physiopathology; Electrocardiography; Equipment Design; Heart Rate; Humans; Methods; Netherlands; Pacemaker, Artificial; Research Design; Sick Sinus Syndrome - diagnosis; Sick Sinus Syndrome - physiopathology; Sick Sinus Syndrome - therapy; Study Protocol; Telemetry; Time Factors; Treatment Outcome; Netherlands
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/1745-6215-15-445

The incidence of sick sinus syndrome will increase due to population ageing. Consequently, this will result in an increase in the number of pacemaker implantations. The atrial lead is usually implanted in the right atrial appendage, but this position may be ineffective for prevention of atrial fibrillation. It has been suggested that pacing distally in the coronary sinus might be more successful in preventing atrial fibrillation episodes. The aim of this trial is to study the efficacy of distal coronary sinus versus right atrial appendage pacing in preventing atrial fibrillation episodes in patients with sick sinus syndrome. This study is designed as a multicenter, randomized controlled trial. Patients with sick sinus syndrome and at least one atrial fibrillation episode of 30 seconds or more in the six months before recruitment will be eligible for participation in this study.All participants will be randomized between pacing distally in the coronary sinus and right atrial appendage. Randomization is stratified for all participating centers. Conventional dual-chamber pacemakers with advanced home monitoring functionality will be implanted. The ventricular lead will be implanted in the right ventricular apex. The first three months of the 36-month follow-up period are considered as run-in time. During the pre-randomization visit and follow-up, an interview, electrocardiogram and pacemaker assessment will be performed, prescribed antiarrhythmic medication will be reviewed and patients will be asked to complete an SF-36 questionnaire. An echocardiographic examination will be conducted in the pre-randomization phase and at the end of each follow-up year. Home monitoring will be used to send daily reports in case of atrial fibrillation episodes. This randomized controlled trial is the first in which home monitoring will be used to compare atrial fibrillation recurrences between pacing in the distal coronary sinus or right atrial appendage. Home monitoring gives the opportunity to accurately detect atrial fibrillation episodes and to study characteristics of atrial fibrillation episodes. Should distal coronary sinus pacing significantly diminish atrial fibrillation recurrences, this study will redefine the preferential location of an atrial lead for preventive pacing. Current Controlled Trials ISRCTN65911661, registered on 8 July 2013.